ES2313886T3 - Nueva proteina quimerica para la prevencion y tratamiento de infeccion por hiv. - Google Patents

Nueva proteina quimerica para la prevencion y tratamiento de infeccion por hiv. Download PDF

Info

Publication number
ES2313886T3
ES2313886T3 ES00918015T ES00918015T ES2313886T3 ES 2313886 T3 ES2313886 T3 ES 2313886T3 ES 00918015 T ES00918015 T ES 00918015T ES 00918015 T ES00918015 T ES 00918015T ES 2313886 T3 ES2313886 T3 ES 2313886T3
Authority
ES
Spain
Prior art keywords
protein
binding
baselineskip
fusion
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00918015T
Other languages
English (en)
Spanish (es)
Inventor
Edward A. Berger
Christie M. Del Castillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2313886T3 publication Critical patent/ES2313886T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES00918015T 1999-03-16 2000-03-16 Nueva proteina quimerica para la prevencion y tratamiento de infeccion por hiv. Expired - Lifetime ES2313886T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12468199P 1999-03-16 1999-03-16
US124681P 1999-03-16

Publications (1)

Publication Number Publication Date
ES2313886T3 true ES2313886T3 (es) 2009-03-16

Family

ID=22416252

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00918015T Expired - Lifetime ES2313886T3 (es) 1999-03-16 2000-03-16 Nueva proteina quimerica para la prevencion y tratamiento de infeccion por hiv.

Country Status (8)

Country Link
EP (1) EP1161455B1 (https=)
JP (1) JP2002538814A (https=)
AT (1) ATE407146T1 (https=)
AU (1) AU765218B2 (https=)
CA (1) CA2361292C (https=)
DE (1) DE60040136D1 (https=)
ES (1) ES2313886T3 (https=)
WO (1) WO2000055207A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925966D0 (en) 1999-11-02 1999-12-29 Petrik Juraj Threapeutic vaccines against variable viruses and other targets
IL141023A0 (en) * 2001-01-22 2002-02-10 Gavish Galilee Bio Appl Ltd Recombinant polypeptides for effective hiv neutralization
DK1390535T3 (da) * 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
ATE481109T1 (de) 2001-10-16 2010-10-15 Us Gov Health & Human Serv Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden
US7368114B2 (en) 2001-10-25 2008-05-06 The United States Of America As Represented By The Department Of Health And Human Services Fusion protein including of CD4
US7566451B2 (en) 2002-05-06 2009-07-28 The United States Of America As Represented By The Department Of Health And Human Services Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency
US7803913B2 (en) 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
WO2004110359A2 (en) * 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Fusion proteins for the treatment of cns
ES2319838B1 (es) * 2006-09-29 2010-02-11 Consejo Superior Investig. Cientificas Uso de inhibidores de la actividad de la proteina filamina a, para la elaboracion de composiciones farmaceuticas, compuestos inhibidores de dicha actividad, composiciones farmaceuticas y sus aplicaciones terapeuticas y procedimiento identificacion de dichos compuestos inhibidores.
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
CN111909278B (zh) 2014-01-27 2024-04-09 分子模板公司 Mhc i类表位递送多肽
AU2016271124C1 (en) * 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
MX2022000896A (es) * 2019-07-24 2022-02-14 Regeneron Pharma Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU735460B2 (en) * 1996-06-14 2001-07-12 Aaron Diamond Aids Research Center, The Uses of a chemokine receptor for inhibiting HIV-1 infection
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A

Also Published As

Publication number Publication date
CA2361292A1 (en) 2000-09-21
EP1161455B1 (en) 2008-09-03
EP1161455A1 (en) 2001-12-12
ATE407146T1 (de) 2008-09-15
AU765218B2 (en) 2003-09-11
JP2002538814A (ja) 2002-11-19
CA2361292C (en) 2012-05-29
WO2000055207A1 (en) 2000-09-21
DE60040136D1 (de) 2008-10-16
AU3889600A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
ES2213148T3 (es) Anticuerpo monoclonal dirigido contra el vih.
US20130189264A1 (en) A novel chimeric protein for prevention and treatment of hiv infection
ES2313886T3 (es) Nueva proteina quimerica para la prevencion y tratamiento de infeccion por hiv.
EP2566493B1 (en) Bifunctional molecules for inactivating hiv and blocking hiv
JPH05505112A (ja) Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
ES2262250T3 (es) Expresion constitutiva de particulas no infecciosas del tipo del vih.
JP2023055875A (ja) Ｈｉｖ融合体を標的とするポリペプチド
US20120213790A1 (en) Methods of treatment using il-16 antagonist peptides
US20110263485A1 (en) Bifunctional Griffithsin Analogs
PT2044950E (pt) Cassetes de imunização adn de vif atenuadas para vacinas genéticas
CZ239694A3 (en) Recombinant human antibody against hiv, cassette for expression, host cell and a pharmaceutical preparation against hiv
WO1998000535A2 (en) Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
EP2291392B1 (en) Bifunctional molecules for inhibiting hiv entry
IE912846A1 (en) New embodiments of the hiv principal neutralizing¹determinant
Li et al. Algal lectins for potential prevention of HIV transmission
AU731975B2 (en) GP120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting HIV infection
US7488481B2 (en) Polypeptides derived from anti-HIV-1 gp120 antibodies that abrogate gp120 binding to CCR5
US8093046B2 (en) CVN-12p1: a recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions
WO2024192203A2 (en) Multispecific anti-hiv antibodies